MENU
+Compare
XOMA
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$23.52
Change
-$1.02 (-4.16%)
Capitalization
277.25M

XOMA XOMA Royalty Corporation Forecast, Technical & Fundamental Analysis

a developer of pharmaceutical preparations

Industry Biotechnology
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for XOMA with price predictions
Feb 21, 2025

XOMA sees MACD Histogram crosses below signal line

XOMA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on February 19, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 57 instances where the indicator turned negative. In of the 57 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XOMA as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 50-day moving average for XOMA moved below the 200-day moving average on February 13, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XOMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for XOMA entered a downward trend on January 22, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for XOMA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XOMA advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

XOMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.271) is normal, around the industry mean (12.496). P/E Ratio (0.000) is within average values for comparable stocks, (84.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). XOMA has a moderately high Dividend Yield (0.020) as compared to the industry average of (0.012). P/S Ratio (28.090) is also within normal values, averaging (251.218).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XOMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XOMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

XOMA is expected to report earnings to fall 81.97% to -28 cents per share on March 06

XOMA Royalty Corporation XOMA Stock Earnings Reports
Q4'24
Est.
$-0.29
Q3'24
Missed
by $1.15
Q2'24
Beat
by $1.10
Q1'24
Missed
by $0.22
Q4'23
Missed
by $1.51
The last earnings report on November 07 showed earnings per share of -159 cents, missing the estimate of -43 cents. With 49.23K shares outstanding, the current market capitalization sits at 277.25M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical preparations

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2200 Powell Street
Phone
+1 510 204-7200
Employees
13
Web
https://www.xoma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMKBX21.66N/A
N/A
Morgan Stanley Inst Emerging Mkts A
TNVIX17.43N/A
N/A
1290 GAMCO Small/Mid Cap Value I
BIDEX10.45-0.03
-0.29%
BlackRock Defensive Advantage EM Instl
VGINX87.02-1.15
-1.30%
JPMorgan US Value R6
MUEUX36.53-0.64
-1.72%
MFS Blended Research Core Equity R4

XOMA and Stocks

Correlation & Price change

A.I.dvisor tells us that XOMA and LYEL have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XOMA and LYEL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XOMA
1D Price
Change %
XOMA100%
-4.16%
LYEL - XOMA
32%
Poorly correlated
+6.17%
PRME - XOMA
32%
Poorly correlated
-5.27%
INVA - XOMA
30%
Poorly correlated
+0.06%
CRBU - XOMA
30%
Poorly correlated
-7.09%
FATE - XOMA
30%
Poorly correlated
-8.09%
More